Search Results
Jul 23, 2026, 09:00 ET GRAL INVESTOR ALERT: GRAIL, Inc. (GRAL) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit- HBSS
laws by GRAIL, Inc. (NASDAQ: GRAL). The suit contends the company misled investors regarding the clinical design and efficacy of its landmark NHS-Galleri cancer screening trial.
More news about: Hagens Berman Sobol Shapiro LLP
Jul 23, 2026, 09:00 ET First Published Clinical Study Demonstrates Feasibility of Fluorescence Imaging in Orthopaedic Surgery
additional resection surgeries and fewer infection complications.About The Royal Orthopaedic Hospital NHS Foundation Trust The Royal Orthopaedic Hospital NHS Foundation Trust is one of the largest specialist orthopaedic units in Europe, offering planned orthopaedic surgery to
More news about: MolecuLight
Jul 22, 2026, 10:07 ET GRAL Deadline Alert: Levi & Korsinsky Reminds Grail, Inc. (GRAL) Investors of Securities Class Action Deadline on August 4, 2026
Deadline Alert: GRAL Investors Who Lost Money After Grail's NHS-Galleri Trial Failed Its Primary Endpoint Have Until August 4, 2026 to Seek Lead Plaintiff Appointment in Securities Class ActionNEW YORK, July 22, 2026
More news about: Levi & Korsinsky, LLP
Jul 22, 2026, 09:35 ET Get A Drip among first providers of newly approved oral Wegovy in the UK
NHS England states that 30% of adults in the UK are living with obesity, and 66% are overweight. In addition, recent analysis from the
More news about: Get A Drip
Jul 22, 2026, 07:00 ET American Heart Association AI Assessment Lab Report Finds Ultromics' EchoGo® Heart Failure May Identify HFpEF Earlier Than Standard Care
Ultromics is redefining cardiovascular care with FDA-cleared, AI-powered tools that enhance echocardiographic diagnosis. Built in partnership with the NHS and Mayo Clinic, its EchoGo® platform helps clinicians detect complex heart diseases earlier and more accurately—using nothing more than a standard ultrasound
More news about: Ultromics
Jul 22, 2026, 06:05 ET GRAL INVESTOR ALERT: GRAIL, Inc. (GRAL) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit- HBSS
laws by GRAIL, Inc. (NASDAQ: GRAL). The suit contends the company misled investors regarding the clinical design and efficacy of its landmark NHS-Galleri cancer screening trial.
More news about: Hagens Berman Sobol Shapiro LLP
Jul 22, 2026, 04:08 ET ivWatch: Innovative Technology Now Available Through UK NHS Supply Chain
www.ivwatch.com.About NHS Supply ChainNHS Supply Chain manages the sourcing, delivery and supply of healthcare products, services and food for NHS trusts and healthcare organizations across England and Wales.Their role is to source, deliver and supply healthcare products, services and food for NHS trusts
More news about: ivWatch, LLC
Jul 22, 2026, 04:08 ET ivWatch: Innovative Technology Now Available Through UK NHS Supply Chain
www.ivwatch.com.About NHS Supply ChainNHS Supply Chain manages the sourcing, delivery and supply of healthcare products, services and food for NHS trusts and healthcare organizations across England and Wales.Their role is to source, deliver and supply healthcare products, services and food for NHS trusts
More news about: ivWatch, LLC
Jul 21, 2026, 16:19 ET INVESTOR NOTICE: GRAIL, Inc. (GRAL) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action- Hagens Berman
laws by GRAIL, Inc. (NASDAQ: GRAL). The suit contends the company misled investors regarding the clinical design and efficacy of its landmark NHS-Galleri cancer screening trial.
More news about: Hagens Berman Sobol Shapiro LLP
Jul 21, 2026, 10:05 ET GRAL Deadline Alert: The Gross Law Firm Reminds GRAIL, Inc. (GRAL) Investors of Securities Class Action Deadline on August 4, 2026
the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of GRAIL's NHS-Galleri trial following the reveal of the top-line results covering the first screening round. Notably, as defendants have since attested, the trial
More news about: The Gross Law Firm
Jul 21, 2026, 06:17 ET Lawsuit Notice: $GRAL Legal News: GRAIL, Inc. Trial Results and 50% Stock Drop Trigger Securities Fraud Class Action
implementation of its test as a national screening program through the United Kingdom's National Health Service ("NHS"), GRAIL conducted the "NHS-Galleri trial." The primary objective of the NHS-Galleri trial was "to show a reduction in late-stage (III-IV) cancers in people who received the Galleri test
More news about: Bleichmar Fonti & Auld LLP
Jul 18, 2026, 14:03 ET GRAIL, Inc. Deadline: GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit
the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of GRAIL's NHS-Galleri trial following the reveal of the top-line results covering the first screening round. Notably, as defendants have since attested, the trial
More news about: THE ROSEN LAW FIRM, P. A.
Jul 17, 2026, 04:39 ET First Patient Dosed in Chemotherapy Induced Peripheral Neuropathy Clinical Trial
PharmaAnanda Pharma is a UK pharmaceutical company providing its MRX1 oral solution to two Phase 2 clinical trials: ENDOCAN (endometriosis pain, funded by NHS Scotland) and ACTiON (CIPN, funded by an NIHR EME grant). The Company works with world-class scientists, including Key Opinion Leaders at the University
More news about: Ananda Pharma Limited
Jul 16, 2026, 10:09 ET GRAL DEADLINE: SueWallSt Reminds Grail, Inc. Investors of Upcoming Securities Class Action Deadline
Time-Sensitive: Allegations Focus on Defendants' Refusal to Share Detailed NHS-Galleri Data, Potentially Concealing Adverse Trendlines From InvestorsNEW YORK, July 16, 2026 /PRNewswire/ -- SueWallSt alerts investors
More news about: SueWallSt.com
Jul 16, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GRAIL, Inc. of Class Action Lawsuit and Upcoming Deadlines - GRAL
action] On February 19, 2026, Grail announced that "primary endpoint of statistically significant Stage III-IV reduction was not observed" in the NHS-Galleri Trial. Grail attributed this shortcoming, in part, to "probably need[ing] a longer follow-up time to be able to [compare the study arms] adequately." On
More news about: Pomerantz LLP
Jul 16, 2026, 09:00 ET INVESTOR NOTICE: GRAIL, Inc. (GRAL) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action- Hagens Berman
laws by GRAIL, Inc. (NASDAQ: GRAL). The suit contends the company misled investors regarding the clinical design and efficacy of its landmark NHS-Galleri cancer screening trial.
More news about: Hagens Berman Sobol Shapiro LLP
Jul 16, 2026, 09:00 ET Priority Health Collaborates With GRAIL as the First Michigan Health Plan to Offer the Galleri® Multi-Cancer Early Detection Blood Test to Employer Plans
evaluation1-3. The Galleri test is backed by a robust clinical evidence program, with more than 380,000 participants across multiple studies, including the NHS-Galleri trial, the first and only randomized controlled trial for an MCED test. The Galleri test has delivered consistent performance across these studies.
More news about: GRAIL, Inc.
Jul 15, 2026, 10:07 ET GRAL Shareholder Alert: Grail, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
Alert: Claims Focus on Alleged Misrepresentations About Whether the NHS-Galleri Trial's Three-Year Design Could Deliver Its Primary Endpoint of Reduced Late-Stage CancersNEW YORK, July 15, 2026 /PRNewswire/
More news about: Levi & Korsinsky, LLP
Jul 15, 2026, 07:01 ET Genesis Automation Healthcare Adds Senior Leaders for Global Sales, Client Success, and Product Ahead of AHRMM26
all three countries."Elizabeth, Patti, and Charles bring exactly the leadership Genesis needs to continue scaling into new hospitals, NHS trusts, and health systems," said Jason Smith, President of Genesis. "Three companies have become one, with one platform and one purpose: protecting
More news about: Genesis Automation Healthcare
Jul 14, 2026, 21:41 ET INVESTOR NOTICE: GRAIL, Inc. (GRAL) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action- Hagens Berman
/PRNewswire/ -- On February 20, 2026, GRAIL, Inc. (NASDAQ: GRAL) shed over $2.2 billion of market capitalization after surprising investors with its NHS-Galleri Trial readout. The news caused huge investor losses and triggered a securities class action lawsuit seeking to represent investors who purchased
More news about: Hagens Berman Sobol Shapiro LLP
Jul 14, 2026, 10:07 ET GRAL UPCOMING DEADLINE : The Gross Law Firm Alerts GRAIL, Inc. Stockholders of Securities Class Action - Contact the Firm
the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of GRAIL's NHS-Galleri trial following the reveal of the top-line results covering the first screening round. Notably, as defendants have since attested, the trial
More news about: The Gross Law Firm
Jul 14, 2026, 06:17 ET GRAL Court News: GRAIL, Inc. Class Action Lawsuit Alleges Securities Fraud on behalf of Investors with Losses
implementation of its test as a national screening program through the United Kingdom's National Health Service ("NHS"), GRAIL conducted the "NHS-Galleri trial." The primary objective of the NHS-Galleri trial was "to show a reduction in late-stage (III-IV) cancers in people who received the Galleri test
More news about: Bleichmar Fonti & Auld LLP
Jul 13, 2026, 14:23 ET GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit
the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of GRAIL's NHS-Galleri trial following the reveal of the top-line results covering the first screening round. Notably, as defendants have since attested, the trial
More news about: THE ROSEN LAW FIRM, P. A.
Jul 13, 2026, 08:55 ET GRAL INVESTOR NOTICE: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman and Dowd LLP Announces
significant reduction in Stage III-IV cancers in Grail's NHS-Galleri trial, while also concealing material adverse facts which reduced the possibility of such an outcome; (ii) in truth, Grail's optimism in achieving the primary endpoint of its NHS-Galleri study fell short of reality; and (iii) the confidence
More news about: Robbins Geller Rudman & Dowd LLP
Jul 13, 2026, 05:03 ET GRAIL, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GRAL
August 4, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Grail described its NHS-Galleri trial in positive terms while concealing adverse facts about the trial's results. Based on these facts, Grail's public statements were false
More news about: DJS Law Group LLP